Avalon GloboCare (NASDAQ:ALBT) (NASDAQ: ALBT) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cell-based therapeutics, exosome-based products and digital health solutions. The company’s primary research efforts are concentrated on engineered exosomes for targeted delivery of therapeutic payloads, immune cell therapies for oncology and infectious diseases, and point-of-care diagnostic tools. Avalon’s platform leverages advanced bioengineering, proprietary exosome isolation technology and precision manufacturing processes to advance pipeline candidates toward clinical evaluation.
Avalon’s lead programs include exosome-mediated delivery systems designed to carry small molecule drugs, nucleic acids and proteins directly to tumor sites, as well as novel cell therapy candidates aimed at reprogramming the body’s immune response against cancer and viral infections. In addition to its pipeline, the company operates a digital health and data analytics division that integrates wearable devices, remote monitoring and AI-driven algorithms to support patient management and real-world evidence collection. This digital arm complements Avalon’s therapeutic platforms by enabling seamless tracking of clinical outcomes and improving trial efficiency.
The company serves global markets, with headquarters in New York and research and development facilities in the United States and Asia. Strategic collaborations with academic institutions, contract development and manufacturing organizations (CDMOs) and clinical research organizations (CROs) support Avalon’s efforts to scale production and accelerate regulatory submissions across multiple jurisdictions. By combining its expertise in bioprocess engineering and translational medicine, Avalon aims to address unmet medical needs in oncology, infectious disease and regenerative medicine.
Avalon GloboCare was founded in 2016 and has since expanded its leadership team to include seasoned professionals in biotechnology, clinical development and operations. Weian Zhao, Ph.D., serves as Chairman and Chief Executive Officer, bringing over two decades of experience in cell therapy and exosome research. The company’s executive team also features experts in regulatory affairs, commercial strategy and digital health integration, positioning Avalon to advance its pipeline toward key clinical milestones and potential commercialization.
